Who's on first for Icahn departee Alex Denner?

After reportedly adding $2 billion to Carl Icahn's (photo) treasure chest, Alex Denner is now off on his own, setting up a new hedge fund that presumably will set out to follow the same biotech blueprint that has worked so well in the past. Report

Suggested Articles

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.

Merck’s Keytruda is battling Bristol Myers' Opdivo in adjuvant melanoma, and it just racked up trial results that will help it even the playing field.